Neurometrix Inc (NASDAQ:NURO) shares saw an uptick in trading volume on Monday . 1,883,733 shares traded hands during trading, an increase of 1,148% from the previous session’s volume of 150,941 shares.The stock last traded at $0.60 and had previously closed at $0.52.
Several research firms recently weighed in on NURO. Zacks Investment Research cut Neurometrix from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. ValuEngine raised Neurometrix from a “hold” rating to a “buy” rating in a report on Monday, April 1st. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Neurometrix in a report on Friday, April 26th.
The company has a market capitalization of $4.61 million, a P/E ratio of 3.70 and a beta of 0.75.
An institutional investor recently raised its position in Neurometrix stock. Renaissance Technologies LLC boosted its stake in shares of Neurometrix Inc (NASDAQ:NURO) by 27.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 389,015 shares of the medical device company’s stock after acquiring an additional 83,500 shares during the period. Renaissance Technologies LLC owned 4.41% of Neurometrix worth $428,000 at the end of the most recent reporting period. 10.38% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Neurometrix (NASDAQ:NURO) Sees Large Volume Increase” was published by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://dakotafinancialnews.com/2019/06/13/neurometrix-nasdaqnuro-sees-large-volume-increase.html.
Neurometrix Company Profile (NASDAQ:NURO)
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
See Also: Momentum Investing
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.